Autosomal Dominant Charcot-Marie-Tooth Disease Type 2 due to Diacylglycerol O-Acyltransferase 2 (DGAT2) Mutation

Autosomal dominant Charcot-Marie-Tooth disease type 2 due to diacylglycerol O-acyltransferase 2 (DGAT2) mutation is an inherited nerve disease that damages the long wires of the peripheral nerves (the axons). It follows an autosomal-dominant pattern (a single faulty copy of the gene can cause disease) and is linked to a change (mutation) in the DGAT2 gene. Children usually start with weakness and thinning (atrophy) of the lower-leg and foot muscles, trouble with balance and walking, and reduced feeling in the feet. Hand tremor and reduced reflexes are also reported. Because the axon is the main problem, this form is classified as CMT type 2 (CMT2), the axonal form of Charcot-Marie-Tooth disease. orpha.net+2NCBI+2

Autosomal dominant CMT type 2 due to DGAT2 is a rare axonal hereditary neuropathy. It typically shows slowly progressive weakness and wasting in the feet and lower legs, high-arched feet (pes cavus) with balance trouble, and sometimes hand involvement and tremor. A 2016 family study identified DGAT2 mutations as a cause of autosomal-dominant CMT2; DGAT2 encodes a key enzyme that completes triglyceride synthesis, linking lipid metabolism to nerve health. Clinical descriptions and registries (Orphanet/GARD) recognize this subtype as very rare; overall CMT management is supportive because no disease-modifying drug is approved yet. Mayo Clinic+5PubMed+5Wiley Online Library+5

The DGAT2 gene makes an enzyme that performs the last step of triglyceride (fat) synthesis, working at the membrane interface between the endoplasmic reticulum and mitochondria. In the first reported family, a missense variant p.Y223H in DGAT2 was found; affected individuals had low blood triglyceride levels, and cell/animal models showed the mutant protein impairs motor-neuron cell growth and axonal branching, pointing to disrupted lipid handling as a driver of axonal degeneration. NCBI+1

---

Other names

• CMT2 due to DGAT2 mutation

• Autosomal dominant axonal CMT (DGAT2-related)

• Charcot-Marie-Tooth disease type 2 (DGAT2)

• Hereditary motor and sensory neuropathy, axonal, due to DGAT2
  (These names all point to the same ultra-rare condition.) orpha.net+1

---

Types

This condition is extremely rare, and only limited families are described, so formal sub-types are not established. Clinically, doctors may group presentations as:

1. Typical childhood-onset axonal CMT2 – slowly progressive lower-limb weakness/atrophy with sensory loss and ataxic, broad-based gait. NCBI

2. Adolescent/young-adult presentation – similar pattern, sometimes with prominent hand tremor and reduced reflexes. NCBI

3. Severe early-onset course – rarer, with faster functional impact, reflecting the variability seen across CMT2 genes. (General CMT2 variability.) cmtausa.org

---

Causes

Core cause: a pathogenic DGAT2 variant (usually dominant) that disrupts triglyceride synthesis and lipid-droplet biology in neurons/Schwann cells, weakening long axons. In the index family this was DGAT2 p.Y223H. PubMed

Because this is a monogenic disease, most entries below describe either (a) molecular/biologic drivers tied to DGAT2 function or (b) modifiers/differentials clinicians assess that can influence severity, timing, or mimic the disorder:

1. Heterozygous pathogenic DGAT2 missense variant (e.g., p.Y223H). PubMed

2. Loss of DGAT2 enzymatic activity → reduced triglyceride formation at ER–mitochondria contact sites. NCBI

3. Disrupted axonal lipid supply needed for membrane maintenance/repair along long nerves. (Mechanistic inference from DGAT2 role.) NCBI

4. Abnormal axonal branching and growth demonstrated in zebrafish expressing mutant DGAT2. PubMed

5. Reduced serum triglycerides seen in the index patient, suggesting systemic lipid effects. PubMed

6. Endoplasmic-reticulum/mitochondrial membrane dysfunction affecting axonal energy/lipid homeostasis. (Mechanistic context.) PubMed

7. Dominant inheritance from an affected parent (vertical transmission); de novo variants can also occur. PubMed

8. Background genetic modifiers in other neuropathy/lipid genes (general CMT2 concept). NCBI

9. Metabolic stressors (e.g., diabetes, dyslipidemia) can worsen any axonal neuropathy and are screened as modifiers. PMC

10. Nutritional deficiencies (B12) are ruled out because they mimic axonal neuropathy; if present, they aggravate symptoms. NCBI

11. Thyroid dysfunction – a common reversible neuropathy cause to exclude in evaluation. NCBI

12. Toxic neuropathies (alcohol, chemotherapy) – important differentials that can add damage. NCBI

13. Entrapment neuropathies (e.g., carpal tunnel) can coexist and amplify weakness/paresthesia. (CMT patients often develop entrapments.) jnnp.bmj.com

14. Immune neuropathies (e.g., CIDP) are evaluated because imaging/nerve size patterns differ and treatment differs. Frontiers

15. Foot/ankle biomechanics (pes cavus) from long-standing denervation can perpetuate falls and pain. NCBI

16. Aging – axons naturally lose reserve; inherited axonopathy can manifest earlier/severer with age. (General CMT concept.) NCBI

17. Infections causing small-fiber injury (differential) – assessed and excluded with labs/biopsy when indicated. PMC

18. Autoimmune conditions – ruled out in work-up of neuropathy to avoid misdiagnosis. NCBI

19. Musculoskeletal deconditioning – secondary cause of fatigue/weakness overlaying neuropathy. (Rehab perspective.) NCBI

20. Other CMT genes (MFN2, GDAP1, etc.)—broad gene panels are used so the specific cause (DGAT2) isn’t missed. Mayo Clinic Laboratories

(Important note: #1–7 reflect the true etiology of DGAT2-CMT2. Items #8–20 are modifiers or look-alikes that clinicians check because they can worsen symptoms or imitate the disease.)

---

Symptoms and signs

Each person’s mix of features can vary, even in the same family, but common, plain-language features include:

1. Weak ankles and feet—difficulty running, frequent sprains. NCBI

2. Foot muscle wasting—thinner calves/feet over time. NCBI

3. High-arched feet (pes cavus) and hammer toes after years of denervation. NCBI

4. Unsteady, wide-based gait (ataxia) with frequent falls. NCBI

5. Numbness or reduced feeling in toes/feet, later in hands. NCBI

6. Hand tremor that can affect fine tasks. NCBI

7. Reduced or absent reflexes, especially at the ankles. NCBI

8. Foot drop—lifting the toes becomes hard, causing tripping. NCBI

9. Cramping or aching in calves/feet after activity. NCBI

10. Problems with balance in the dark (sensory ataxia). NCBI

11. Tingling/burning (paresthesias), usually mild to moderate. NCBI

12. Hand weakness—buttoning, jar opening become harder over time. NCBI

13. Fatigue with walking/standing due to weak distal muscles. NCBI

14. Cold, pale feet from less muscle pump and autonomic involvement in some. NCBI

15. Slow progression over years (not rapid). NCBI

---

Diagnostic tests

A) Physical examination

1. Neurologic strength and reflex testing – your doctor grades muscle strength and taps reflexes; weak foot/ankle muscles and reduced ankle reflexes fit CMT2. NCBI

2. Detailed sensory testing – checks vibration (tuning fork), position sense, and light touch; loss starts in toes/feet. NCBI

3. Gait and posture assessment – watching heel-to-toe, toe/heel walking, and overall balance to document ataxia and foot drop. NCBI

4. Foot structure inspection – looks for pes cavus/hammer toes, calluses, and ankle instability that come with long-standing denervation. NCBI

B) Manual/bedside functional tests

5. Romberg test – standing with feet together, then eyes closed; sway suggests sensory ataxia from nerve loss. NCBI

6. Tandem (heel-to-toe) walk – challenges balance and reveals subtle ataxia. NCBI

7. 10-Meter Walk Test – timed short walk to track walking speed and fall risk over time. (Functional tracking in neuropathies.) NCBI

8. Nine-Hole Peg Test (hands) – times fine finger dexterity; useful when hand tremor/weakness appears. NCBI

C) Laboratory & pathology

9. Fasting lipid panel – may show low triglycerides in DGAT2-CMT2 (reported in the index case), supporting the link to lipid synthesis. PubMed

10. Creatine kinase (CK) – usually normal or mildly raised; helps exclude primary muscle disease. NCBI

11. Glucose/HbA1c – screens diabetes, a common cause of axonal neuropathy that can worsen symptoms. PMC

12. Vitamin B12 ± methylmalonic acid – excludes a treatable axonal neuropathy mimic. NCBI

13. Genetic testing – NGS neuropathy panel or exome including DGAT2 confirms the molecular cause and rules out >150 other neuropathy genes. Mayo Clinic Laboratories

14. Skin biopsy for intraepidermal nerve fiber density (IENFD) – a tiny 3-mm punch biopsy counts small nerve fibers; reduced counts support neuropathy when electrodiagnostics are borderline. JAMA Network

D) Electrodiagnostic studies

15. Nerve conduction studies (NCS) – show axonal changes (low amplitudes with relatively preserved velocities) characteristic of CMT2. NCBI

16. Electromyography (EMG) – needle test of muscles demonstrates chronic denervation/reinnervation patterns. NCBI

17. Late responses (F-waves/H-reflex) – help characterize proximal conduction and reflex arcs when standard NCS are limited. NCBI

E) Imaging

18. Peripheral nerve ultrasound – can show diffuse nerve enlargement patterns in CMT; useful to distinguish inherited from inflammatory neuropathies in context. jnnp.bmj.com+1

19. MR neurography – visualizes nerve signal/size along limbs and plexus; adjunct to support diagnosis and exclude other causes. PMC

20. Foot/ankle X-rays – document pes cavus/contractures that guide bracing and orthopedic care. NCBI

Non-pharmacological treatments (therapies & others)

1) Individualized physiotherapy program.
A tailored, progressive plan that mixes strengthening of remaining motor units, endurance blocks, flexibility, and task-specific gait drills improves daily activities and confidence. Programs favor low-impact, repetitive work with rest breaks to avoid overuse. Evidence syntheses in CMT suggest strength/endurance training can improve function, even though disease progression continues. PMC+1

Purpose & mechanism: build reserve and coordination in partly denervated muscles; plasticity in central patterns and improved recruitment lower effort for walking. PMC

2) Balance and proprioceptive training.
Static/dynamic balance tasks (single-leg stance with supports, compliant surfaces, perturbations) reduce falls and improve gait stability. Programs often integrate ankle strategy work and visual substitution. MDPI

Purpose & mechanism: repeated sensory-motor practice recalibrates balance responses despite distal sensory loss. MDPI

3) Daily stretching of calves, hamstrings, plantar fascia.
Short, frequent stretches help delay contractures and ease brace fitting; stretching is a standard first-line element in CMT care pathways. Hospital for Special Surgery

Purpose & mechanism: reduces muscle-tendon stiffness and maintains joint range to keep a plantigrade foot posture longer. Hospital for Special Surgery

4) Ankle-foot orthoses (AFOs).
Light carbon or hinged AFOs counter foot-drop, stabilize the ankle, and improve toe clearance. Useful early while deformity is flexible. PM&R KnowledgeNow

Purpose & mechanism: external moment resists plantarflexion/inversion, improving swing-phase clearance and reducing falls. PM&R KnowledgeNow

5) Custom footwear and insoles.
Wide toe boxes, lateral wedges, and cushioned insoles offload callosities and accommodate cavovarus alignment. PMC

Purpose & mechanism: pressure redistribution lowers pain and skin breakdown under metatarsal heads/heels. PMC

6) Occupational therapy (hands and ADLs).
Hand-strength conservation, adaptive equipment (button hooks, built-up pens), and energy-conservation strategies maintain independence. Medscape

Purpose & mechanism: compensates for distal weakness and sensory loss with tools and task simplification. Medscape

7) Falls-prevention home program.
Lighting, railings, removing loose rugs, and footwear audits reduce fall risk in sensory ataxia. Mayo Clinic

Purpose & mechanism: environmental hazard reduction + cueing stabilize gait. Mayo Clinic

8) Pain self-management education.
Pacing, sleep hygiene, and cognitive strategies augment medications for neuropathic pain. Medscape

Purpose & mechanism: reduces central sensitization and improves coping with chronic neuropathic pain. Medscape

9) TENS (trial).
Some patients report paresthesia-based pain relief; evidence is mixed, but it’s safe to trial alongside rehab. Medscape

Purpose & mechanism: gate-control modulation and endogenous opioid release may blunt pain signaling. Medscape

10) Warm-water and low-impact aerobic exercise.
Cycling, pool walking, and elliptical training maintain fitness with minimal joint stress. PMC

Purpose & mechanism: cardiovascular conditioning and improved mitochondrial efficiency lessen fatigue during ambulation. PMC

11) Core and hip-abductor strengthening.
Proximal conditioning compensates for distal weakness to steady the pelvis and knee during stance. MDPI

Purpose & mechanism: better proximal control reduces ankle inversion moments and trips. MDPI

12) Sensory cueing and vision strategies.
Using visual feedback, textured insoles, or trekking poles helps steadiness on uneven terrain. PMC

Purpose & mechanism: augments impaired proprioception with alternate sensory inputs. PMC

13) Skin and foot-care protocol.
Daily checks, moisturizers, callus care, and blister prevention lower ulcer risk in numb feet. Hospital for Special Surgery

Purpose & mechanism: early detection prevents infections and nonhealing wounds. Hospital for Special Surgery

14) Hand-wrist supports and ergonomic keyboards.
Neutral-position splints and ergonomic devices reduce overuse pain with fine-motor tasks. Medscape

Purpose & mechanism: mechanical support unloads weak intrinsic hand muscles. Medscape

15) Heat for cramps; cautious cooling for burning pain.
Simple modalities offer short-term relief and improve brace tolerance. Medscape

Purpose & mechanism: thermal modulation alters muscle spindle and cutaneous nociceptor activity. Medscape

16) Structured fatigue management.
Scheduling difficult tasks in “best energy” windows and using rests maintains participation. Medscape

Purpose & mechanism: pacing prevents overwork weakness and reduces fall risk. Medscape

17) Genetic counseling for families.
Explains autosomal-dominant inheritance, variable expressivity, and options for testing relatives. NCBI

Purpose & mechanism: informed decisions about testing, family planning, and early rehab enrollment. NCBI

18) Mental-health support.
CBT or supportive therapy can reduce distress, catastrophizing, and pain interference. Medscape

Purpose & mechanism: cognitive reframing improves quality of life in chronic neurological disease. Medscape

19) Community exercise & peer support.
Supervised group classes sustain adherence; peer groups share adaptive tips. PMC

Purpose & mechanism: social reinforcement improves long-term engagement with beneficial activity. PMC

20) Periodic reassessment for bracing vs surgery.
As deformity stiffens, orthoses may underperform; timely surgical referral prevents fixed malalignment. NCBI

---

Drug treatments

Important note: the following medicines are not approved to treat or slow CMT; they are used to manage symptoms like neuropathic pain or cramps. Indications below come from FDA labels (accessdata.fda.gov) for conditions such as diabetic peripheral neuropathy (DPN), post-herpetic neuralgia (PHN), fibromyalgia, or general pain. Clinicians may prescribe off-label for CMT-related pain. Medscape

1) Duloxetine (Cymbalta) — SNRI.
Dose & time: start 30–60 mg daily; typical 60 mg/day; continuous. Purpose: reduce neuropathic pain and improve function. Mechanism: potentiates descending serotonergic/noradrenergic inhibition in the dorsal horn. Side effects: nausea, somnolence, dry mouth, sweating; suicidality warning. FDA label indications include DPN and fibromyalgia; off-label for CMT pain. FDA Access Data+1

2) Pregabalin (Lyrica / Lyrica CR) — alpha-2-delta ligand.
Dose & time: start 75 mg bid (150 mg/day), titrate to 300–450 mg/day as needed; daily. Purpose: neuropathic pain relief. Mechanism: reduces calcium influx at overactive terminals, lowering excitatory neurotransmission. Side effects: dizziness, somnolence, weight gain; suicidality warning. FDA-approved for DPN, PHN, fibromyalgia, neuropathic pain in spinal cord injury; off-label for CMT pain. FDA Access Data+2FDA Access Data+2

3) Gabapentin (Neurontin) — alpha-2-delta ligand.
Dose & time: titrate from 300 mg at night to 900–3600 mg/day divided; daily. Purpose: neuropathic pain. Mechanism: similar to pregabalin. Side effects: sedation, ataxia, edema. Label includes neuralgia indications; used off-label widely for neuropathic pain. FDA Access Data+1

4) Capsaicin 8% patch (Qutenza) — high-concentration topical.
Dose & time: in-clinic 30–60-minute application to painful area at intervals (e.g., every 3 months). Purpose: focal neuropathic pain. Mechanism: defunctionalizes TRPV1 nociceptors, reducing spontaneous firing. Side effects: local burning, erythema; avoid eyes/mucosa. FDA-approved for PHN and DPN of the feet; can be considered for localized CMT pain. FDA Access Data+2FDA Access Data+2

5) Lidocaine 5% patch (Lidoderm) — topical sodium-channel blocker.
Dose & time: up to three patches, 12 hours on/12 hours off, to most painful area. Purpose: localized neuropathic pain. Mechanism: stabilizes neuronal membranes via voltage-gated sodium channel blockade. Side effects: local irritation, minimal systemic effects. FDA-approved for PHN; used off-label in other focal neuropathic pain states. FDA Access Data+1

6) Tramadol — centrally acting analgesic (opioid/SNRI).
Dose & time: 50–100 mg q4–6h PRN (max per label); short-term rescue. Purpose: second-line rescue for severe flares when neuropathic agents insufficient. Mechanism: mu-opioid agonism + monoamine reuptake inhibition. Side effects: nausea, constipation, dizziness, dependence; caution with serotonergic drugs. FDA label supports use for pain (not neuropathy-specific). Medscape

7) TCAs (e.g., amitriptyline, nortriptyline) — serotonin/norepinephrine reuptake inhibitors with sodium-channel effects.
Dose & time: low-dose at night (10–25 mg), titrate to effect; nightly. Purpose: neuropathic pain and sleep. Mechanism: enhances descending inhibition and membrane stabilization. Side effects: anticholinergic effects, QT risk, sedation. Common guideline-supported option; label indications vary by product. Medscape

8) Venlafaxine ER — SNRI.
Dose & time: 37.5–225 mg/day; daily. Purpose: neuropathic pain where duloxetine not tolerated. Mechanism: serotonergic/noradrenergic reuptake inhibition. Side effects: BP elevation, nausea, insomnia. Evidence extrapolated from neuropathic pain literature; label indications include depression/anxiety. Medscape

9) Topical diclofenac gel — NSAID for musculoskeletal pain.
Dose & time: per label to painful joints/soft tissues that coexist (not nerve pain). Purpose: helps secondary joint/soft-tissue pain from abnormal gait. Mechanism: local COX inhibition. Side effects: skin irritation. Medscape

10) Baclofen — antispasticity agent.
Dose & time: 5 mg tid up-titrated; daily. Purpose: cramps/spasticity if present; not all CMT patients need it. Mechanism: GABA_B agonism in spinal cord. Side effects: sedation, weakness. Medscape

11) Oxcarbazepine/carbamazepine — sodium-channel blockers.
Dose & time: titrated daily dosing. Purpose: paroxysmal neuralgias if present. Mechanism: stabilizes hyperexcitable membranes. Side effects: hyponatremia, rash. Medscape

12) NSAIDs (ibuprofen/naproxen) — analgesics.
Dose & time: per label PRN. Purpose: musculoskeletal aches from overuse or bracing—not neuropathic pain per se. Mechanism: COX blockade. Side effects: GI/renal risks. Medscape

13) Magnesium (as medicine for cramps).
Dose & time: individualized; caution in renal disease. Purpose: nocturnal cramp reduction for some patients; evidence variable. Mechanism: calcium channel and NMDA modulation. Medscape

14) Topical compounded mixtures (e.g., lidocaine + low-dose TCA).
Dose & time: applied to focal pain zones; clinician-supervised. Purpose: focal neuropathic pain when patches insufficient. Mechanism: local sodium-channel + monoaminergic effects. Medscape

15) Serotonergic sleep adjuncts (low-dose trazodone).
Dose & time: 25–50 mg at night. Purpose: improve sleep continuity when pain disrupts rest. Mechanism: 5-HT2 antagonism and antihistaminic effects. Medscape

16) Capsaicin low-strength creams (OTC).
Dose & time: thin layer 3–4×/day to focal areas. Purpose: mild burning/aching pain. Mechanism: TRPV1 desensitization. Medscape

17) Lidocaine 4% OTC patches.
Dose & time: per label to localized pain areas; daily. Purpose: focal pain when prescribed 5% is not used. Mechanism: voltage-gated sodium channel blockade. Medscape

18) Acetaminophen (paracetamol).
Dose & time: per label PRN. Purpose: background analgesia for musculoskeletal discomfort; not neuropathic pain per se. Mechanism: central COX and serotonergic pathways. Medscape

19) Short steroid course (rare).
Note: generally not useful for hereditary neuropathy; reserved for alternative etiologies (e.g., compressive radiculopathy) under specialist care. Medscape

20) Avoid chronic strong opioids.
Reason: limited benefit in chronic neuropathic pain and higher risk of dependence and falls; reserve only for exceptional, specialist-supervised cases. Medscape

---

Dietary “molecular” supplements

Supplements do not treat or slow CMT2-DGAT2. Some have evidence for other neuropathies (often diabetic), and results are mixed. Always discuss with a clinician, especially if you take prescription medicines.

1) Alpha-lipoic acid (ALA).
Some trials showed symptom improvement with IV ALA 600 mg/day for 3 weeks; long-term oral results are inconsistent. ALA acts as an antioxidant and may improve microvascular and mitochondrial function in nerve tissue. Typical oral regimens in studies range 600–1200 mg/day; watch for GI upset and hypoglycemia in diabetics. PubMed+1

2) Acetyl-L-carnitine (ALC).
Meta-analysis suggests moderate pain reduction in peripheral neuropathies and possible neurotrophic effects, but one chemotherapy-induced neuropathy trial showed worsening over time—so avoid in that setting. Doses in studies: 500–1000 mg two or three times daily. Mechanism: supports mitochondrial fatty-acid transport and nerve regeneration. PLOS+2PubMed+2

3) Benfotiamine (vitamin B1 derivative).
Some randomized data show reduced neuropathy scores in diabetic neuropathy; evidence remains mixed. Typical research doses 300–600 mg/day. Mechanism: reduces advanced glycation and oxidative stress. PubMed+1

4) Vitamin B12 (cyanocobalamin or methylcobalamin) — when deficient.
If blood B12 is low or borderline with neurologic signs, high-dose oral 1–2 mg/day can be as effective as injections for correction; dosing varies by cause. Mechanism: supports myelin and DNA synthesis. (Do not supplement high doses without confirming need.) American Academy of Family Physicians+2nhs.uk+2

5) Omega-3 (fish-oil EPA/DHA).
There is biologic rationale and mixed early data for reducing neuroinflammation in neuropathies; high-quality trials are limited outside oncology settings. Typical doses studied range 1–3 g/day EPA+DHA; watch for bleeding risk with anticoagulants. PubMed+1

6) Vitamin D — when deficient.
Correcting deficiency may improve musculoskeletal pain and falls risk; test and replete per guidelines (often 1000–2000 IU/day, individualized). Mechanism: neuromuscular and immune modulation. Medscape

7) Curcumin preparations.
Preclinical and small human studies suggest anti-inflammatory/antioxidant effects that could modulate neuropathic pain, but clinical evidence is limited; dosing varies by product. Medscape

8) Coenzyme Q10.
Potential mitochondrial support; human neuropathy data are limited; typical supplemental doses 100–300 mg/day. Medscape

9) Magnesium (again, as supplement).
May reduce cramps in some individuals; check kidney function; common doses 200–400 mg elemental magnesium/day. Medscape

10) Gamma-linolenic acid (evening primrose oil).
Some small studies in diabetic neuropathy suggest benefit; robust evidence is lacking. Typical supplemental amounts vary (consult clinician). Medscape

---

Immunity booster / regenerative / stem-cell” drugs

At present, no FDA-approved “immune booster,” regenerative medicine, gene therapy, or stem-cell product is approved to treat CMT (including DGAT2-related CMT2). Management is supportive, and surgery corrects deformities. For pain, we rely on medications with FDA labels for other neuropathic conditions, as listed above. Using FDA labels as sources: pregabalin, duloxetine, lidocaine patches, and capsaicin patches have approved indications for other neuropathic pains, not CMT itself. FDA Access Data+4Mayo Clinic+4FDA Access Data+4

If you are exploring regenerative strategies, the leading edge is research, not approved care: pathways connect lipid handling (DGAT2) and axonal maintenance, suggesting future targets; but translation to therapy is still preclinical/early clinical. Always avoid unregulated “stem-cell” clinics. Cell

---

Surgeries (procedures & why they’re done)

1) Soft-tissue balancing with plantar fascia release and tendon transfers (e.g., posterior tibial tendon transfer).
What is done: releases tight plantar fascia; transfers stronger tendons to dorsiflexors/everters to correct muscle imbalance. Why: addresses dynamic cavovarus components and foot-drop to achieve a plantigrade, shoe-able foot while preserving motion when deformity is flexible. PubMed+1

2) First-metatarsal dorsiflexion osteotomy.
What is done: a wedge of bone is removed from the first metatarsal to lift a plantar-flexed first ray. Why: rebalances forefoot and reduces varus at the hindfoot by correcting the apex of deformity. upload.orthobullets.com

3) Calcaneal (hindfoot) osteotomy.
What is done: lateralizing or closing-wedge cuts realign the heel from varus toward neutral. Why: corrects fixed hindfoot varus when soft tissues alone are insufficient. PMC

4) Midfoot osteotomies.
What is done: corrective cuts through cuneiforms/cuboid to realign a rigid cavus midfoot. Why: distributes plantar pressures and improves contact area to relieve pain and callosities. RSNA Publications

5) Arthrodesis (fusion) procedures (e.g., triple arthrodesis) when deformity is rigid/arthritic.
What is done: fuses painful, deformed joints to lock in plantigrade alignment. Why: when joints are stiff or degenerated, fusion sacrifices motion to achieve stable alignment and pain relief. NCBI+1

Outcomes data show pain reduction, improved footwear tolerance, and alignment benefits after algorithmic reconstruction, though long-term function depends on underlying muscle weakness. upload.orthobullets.com+1

---

Prevention tips

1. Daily foot checks to spot blisters or pressure areas early. Hospital for Special Surgery

2. Keep nails and skin healthy; professional podiatry for calluses. Hospital for Special Surgery

3. Wear supportive shoes with custom insoles; avoid high heels/slides. PMC

4. Use braces or sticks when advised to reduce trips/falls. PM&R KnowledgeNow

5. Maintain strength, flexibility, and balance with a steady program. PMC

6. Space activities and rest to avoid overwork weakness. Medscape

7. Protect numb feet from heat/cold to prevent burns or frostbite. Medscape

8. Optimize vitamin D and B12 if deficient after testing. American Academy of Family Physicians

9. Manage weight and comorbidities (diabetes, thyroid) that worsen neuropathy. Medscape

10. Plan periodic reviews with neuromuscular and foot/ankle specialists. NCBI

---

What to eat and what to avoid

What to eat: a balanced, anti-inflammatory pattern—vegetables, fruits, whole grains, legumes, nuts, fish (omega-3 sources), lean proteins, and adequate calcium/vitamin D—supports general nerve and muscle health. For anyone with low B12 (more common with vegan diets or malabsorption), fortified foods or supervised supplementation is important. American Academy of Family Physicians

What to avoid or limit: excessive alcohol (neurotoxic), smoking (microvascular harm), ultra-processed foods high in refined sugars and trans-fats (systemic inflammation), and megadose supplements without a clinical indication (possible interactions/side effects). Medscape

---

When to see a doctor

See your neuromuscular clinician now if you have: rapidly worsening weakness or falls; new severe foot pain or skin wounds; braces that suddenly hurt or no longer fit; new hand weakness affecting work/self-care; or new bladder/bowel symptoms (to rule out other causes). Regular follow-ups should check strength, balance, skin, footwear/bracing fit, and whether surgical alignment would help. NCBI

---

FAQs

1) Is DGAT2-related CMT2 really autosomal dominant?
Yes—families with heterozygous DGAT2 variants show dominant transmission of axonal CMT2. PubMed+1

2) What does DGAT2 do?
DGAT2 catalyzes the final step of triglyceride synthesis, linking lipid handling to axonal health. NCBI+1

3) Are there cures or disease-modifying drugs?
No approved disease-modifying drugs yet; treatment is supportive (rehab, bracing, surgery for deformities, pain control). Mayo Clinic

4) Which pain medicines are most used?
Duloxetine, pregabalin, gabapentin, topical lidocaine, and capsaicin patches are common—approved for other neuropathic indications and used off-label in CMT. FDA Access Data+4FDA Access Data+4FDA Access Data+4

5) Do supplements help?
Some (e.g., ALA, benfotiamine) have mixed evidence in diabetic neuropathy; they don’t treat CMT itself. Test-and-treat true deficiencies (e.g., B12). PubMed+2PubMed+2

6) Can exercise make me worse?
Appropriate, paced exercise helps function; avoid overuse and high-impact loads. PMC

7) When is surgery considered?
When deformity becomes fixed or bracing fails to keep a plantigrade foot; goals are alignment, shoe wear, and pain relief. PubMed+1

8) Which surgeries are typical?
Soft-tissue releases/tendon transfers, osteotomies, and—if rigid—arthrodesis. RSNA Publications

9) Are AFOs forever?
Not always; needs change. Reassess regularly; earlier bracing can delay falls and skin injury. PM&R KnowledgeNow

10) What about gene or stem-cell therapy right now?
No FDA-approved products for CMT; beware unregulated clinics. Research is ongoing. Mayo Clinic

11) Will my life span be shortened?
Most people with CMT have normal life expectancy; disability varies. Mayo Clinic

12) Can this affect my hands?
Yes, especially later—fine-motor tasks can be supported with OT and adaptive devices. Medscape

13) Should family members be tested?
Genetic counseling and targeted testing are reasonable in autosomal-dominant families. NCBI

14) Which specialists should I see?
Neuromuscular neurologist/physiatrist, physical/occupational therapists, orthotist, foot-and-ankle surgeon familiar with CMT. Medscape

15) Where can I read more about CMT care?
GeneReviews’ CMT overview is an excellent clinician/lay resource. NCBI

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: October 01, 2025.